君實生物-B(01877.HK)擬出資1000萬元參與斯微生物A+輪融資並獲其2.86%股權
格隆匯2月5日丨君實生物-B(01877.HK)公告,2020年2月3日,上海君實生物醫藥科技股份有限公司(以下簡稱“公司”)與斯微(上海)生物科技有限公司(以下簡稱“斯微生物”)及其現有股東簽署了《關於斯微(上海)生物科技有限公司A+輪增資協議書》,公司擬出資1000萬元人民幣參與斯微生物A+輪融資並獲得其2.86%的股權。
斯微生物是國內較早開展mRNA藥物研發生產的平台型企業,本次投資有助於公司與斯微生物優勢互補,未來合作開展創新藥物和創新聯合療法的開發,對公司業務發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.